Skip to content

A single-center, randomized, placebo-controlled parallel-group clinical study on Banxia Zhuli Qu for the treatment of chronic cough with phlegm-dampness obstructing the lung syndrome

A single-center, randomized, placebo-controlled parallel-group clinical study on Banxia Zhuli Qu for the treatment of chronic cough with phlegm-dampness obstructing the lung syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002617
Enrollment
Unknown
Registered
2025-12-30
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cough

Interventions

Experimental Group:Half Summer Bamboo Extract (Dosage form: Decoction
provided by Ya'an Xunkang Pharmaceutical Co., Ltd.), 15g per day, boiled into 2 packets, take 1 packet each time, twice a day, take after meals while warm.
Control Group:Control group: Half Summer Bamboo Simulated Agent (Dosage form: Decoction
provided by Yaan Xunkang Pharmaceutical Co., Ltd.), 15g per day, 1 bag per dose, twice daily, taken warm after meals.

Sponsors

Guangzhou Medical University First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.The clinical diagnosis is chronic cough; 2.Traditional Chinese Medicine (TCM) differential diagnosis is phlegm-dampness obstructing the lungs; 3.Age between 18 and 70 years old; 4.Voluntarily participating in this clinical trial and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. ALT, AST > 1.5 times the upper limit of normal reference values or Scr > upper limit of normal reference values; 2. History of long-term excessive alcohol consumption or substance abuse; 3. Severe underlying diseases of the heart, liver, kidneys, digestive system, or hematopoietic system; 4. Intellectual disabilities or mental disorders; 5. Pregnant, breastfeeding women, or those planning to conceive; 6. History of allergy to components of the investigational drug; 7. Investigators deem it inappropriate to participate in this clinical trial; 8. Use of other cough-relieving medications (Chinese medicine, traditional Chinese medicine, Western medicine, etc.) within the past week; 9. Participants who have enrolled in other drug clinical trials within the past 30 days.

Design outcomes

Primary

MeasureTime frame
visual analogue scale,VAS;cough evaluation test,CET;

Secondary

MeasureTime frame
Leicester cough questionnaire,LCQ;Hull airway reflux questionnaire,HARQ;TCM Syndrome Score;

Countries

China

Contacts

Public ContactXia Xinhua

Guangzhou Medical University Affiliated First Hospital

star1124@163.com18928868135

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026